GPX2 and exocrine pancreatic carcinoma: In the analysis performed in UALCAN, the highest GPX2 expression occurred in colorectal carcinoma patients, followed by pancreatic carcinoma patients, in which GPX2 expression is approximately 85% with respect to the expression observed in colorectal carcinoma.